Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Norihito Shibata is active.

Publication


Featured researches published by Norihito Shibata.


Cell | 2012

Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses

Nathanael J. Spann; Lana X. Garmire; Jeffrey G. McDonald; David S. Myers; Stephen B. Milne; Norihito Shibata; Donna Reichart; Jesse N. Fox; Iftach Shaked; Daniel Heudobler; Christian R. H. Raetz; Elaine W. Wang; Samuel Kelly; M. Cameron Sullards; Robert C. Murphy; Alfred H. Merrill; H. Alex Brown; Edward A. Dennis; Andrew C. Li; Klaus Ley; Sotirios Tsimikas; Eoin Fahy; Shankar Subramaniam; Oswald Quehenberger; David W. Russell; Christopher K. Glass

Inflammation and macrophage foam cells are characteristic features of atherosclerotic lesions, but the mechanisms linking cholesterol accumulation to inflammation and LXR-dependent response pathways are poorly understood. To investigate this relationship, we utilized lipidomic and transcriptomic methods to evaluate the effect of diet and LDL receptor genotype on macrophage foam cell formation within the peritoneal cavities of mice. Foam cell formation was associated with significant changes in hundreds of lipid species and unexpected suppression, rather than activation, of inflammatory gene expression. We provide evidence that regulated accumulation of desmosterol underlies many of the homeostatic responses, including activation of LXR target genes, inhibition of SREBP target genes, selective reprogramming of fatty acid metabolism, and suppression of inflammatory-response genes, observed in macrophage foam cells. These observations suggest that macrophage activation in atherosclerotic lesions results from extrinsic, proinflammatory signals generated within the artery wall that suppress homeostatic and anti-inflammatory functions of desmosterol.


Proceedings of the National Academy of Sciences of the United States of America | 2001

Supernatant protein factor, which stimulates the conversion of squalene to lanosterol, is a cytosolic squalene transfer protein and enhances cholesterol biosynthesis

Norihito Shibata; Makoto Arita; Yuko Misaki; Naoshi Dohmae; Koji Takio; Teruo Ono; Keizo Inoue; Hiroyuki Arai

Squalene epoxidase, a membrane-associated enzyme that converts squalene to squalene 2,3-oxide, plays an important role in the maintenance of cholesterol homeostasis. In 1957, Bloch and colleagues identified a factor from rat liver cytosol termed “supernatant protein factor (SPF),” which promotes the squalene epoxidation catalyzed by rat liver microsomes with oxygen, NADPH, FAD, and phospholipid [Tchen, T. T. & Bloch, K. (1957) J. Biol. Chem. 226, 921–930]. Although purification of SPF by 11,000-fold was reported, no information is so far available on the primary structure or biological function of SPF. Here we report the cDNA cloning and expression of SPF from rat and human. The encoded protein of 403 amino acids belongs to a family of cytosolic lipid-binding/transfer proteins such as α-tocopherol transfer protein, cellular retinal binding protein, yeast phosphatidylinositol transfer protein (Sec14p), and squid retinal binding protein. Recombinant SPF produced in Escherichia coli enhances microsomal squalene epoxidase activity and promotes intermembrane transfer of squalene in vitro. SPF mRNA is expressed abundantly in the liver and small intestine, both of which are important sites of cholesterol biosynthesis. SPF is expressed significantly in isolated hepatocytes, but the expression level was markedly decreased after 48 h of in vitro culture. Moreover, SPF was not detectable in most of the cell lines tested, including HepG2 and McARH7777 hepatomas. Transfection of SPF cDNA in McARH7777 significantly stimulated de novo cholesterol biosynthesis. These data suggest that SPF is a cytosolic squalene transfer protein capable of regulating cholesterol biosynthesis.


Genes to Cells | 2005

Inhibition of cholesterol biosynthesis by 25-hydroxycholesterol is independent of OSBP.

Taki Nishimura; Takao Inoue; Norihito Shibata; Azusa Sekine; Wakako Takabe; Noriko Noguchi; Hiroyuki Arai

25‐hydroxycholesterol (25‐HC) is a potent suppressor of cholesterol synthesis gene transcription in cultured cells. A high affinity binding protein for 25‐HC, oxysterol‐binding protein (OSBP), has been identified from tissue cytosol. OSBP translocates from the cytosol to the Golgi apparatus membranes after addition of 25‐HC to cell cultures and is thought to mediate 25‐HC action on cholesterol metabolism through association to the Golgi apparatus. However, direct evidence to prove this hypothesis was lacking. In this study, we knocked down expression of OSBP by using duplex siRNAs specific for OSBP to examine the relationship between OSBP and 25‐HC‐induced inhibition of cholesterol synthesis gene transcription. We found that decreasing OSBP expression by ∼90% did not affect 25‐HC‐induced inhibition of transcription of 3‐hydoxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase and squalene epoxidase to any extent. Exogenous lysophosphatidylcholine (LPC), which is known to cause the efflux of cellular cholesterol into the medium and to increase cholesterol synthesis, was found to rescue the 25‐HC‐induced down‐regulation of sterol regulated genes, while LPC did not affect 25‐HC‐induced association of OSBP with the Golgi apparatus. These results suggest that inhibition of cholesterol biosynthesis genes by 25‐HC is OSBP‐independent.


Cell Death and Disease | 2014

Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway

Nobumichi Ohoka; Katsunori Nagai; Takayuki Hattori; Keiichiro Okuhira; Norihito Shibata; Nobuo Cho; Mikihiko Naito

The selective degradation of target proteins with small molecules is a novel approach to the treatment of various diseases, including cancer. We have developed a protein knockdown system with a series of hybrid small compounds that induce the selective degradation of target proteins via the ubiquitin–proteasome pathway. In this study, we designed and synthesized novel small molecules called SNIPER(TACC3)s, which target the spindle regulatory protein transforming acidic coiled-coil-3 (TACC3). SNIPER(TACC3)s induce poly-ubiquitylation and proteasomal degradation of TACC3 and reduce the TACC3 protein level in cells. Mechanistic analysis indicated that the ubiquitin ligase APC/CCDH1 mediates the SNIPER(TACC3)-induced degradation of TACC3. Intriguingly, SNIPER(TACC3) selectively induced cell death in cancer cells expressing a larger amount of TACC3 protein than normal cells. These results suggest that protein knockdown of TACC3 by SNIPER(TACC3) is a potential strategy for treating cancers overexpressing the TACC3 protein.


Cancer Science | 2013

Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells

Keiichiro Okuhira; Yosuke Demizu; Takayuki Hattori; Nobumichi Ohoka; Norihito Shibata; Tomoko Nishimaki-Mogami; Haruhiro Okuda; Masaaki Kurihara; Mikihiko Naito

Manipulation of protein stability with small molecules has a great potential for both basic research and clinical therapy. Recently, we have developed a series of hybrid small molecules named SNIPER (Specific and Non‐genetic IAP‐dependent Protein ERaser) that induces degradation of target proteins via ubiquitin‐proteasome system. Here we report the activities of SNIPER(ER) that targets estrogen receptor alpha (ERα) for degradation. SNIPER(ER) induced degradation of ERα and inhibited estrogen‐dependent expression of pS2 gene in an estrogen‐dependent breast cancer cell line MCF‐7. A proteasome inhibitor MG132 and siRNA‐mediated downregulation of cIAP1 abrogated the SNIPER(ER)‐induced ERα degradation, suggesting that the ERα is degraded by proteasome subsequent to cIAP1‐mediated ubiquitylation. Intriguingly, after the ERα degradation, the SNIPER(ER)‐treated MCF‐7 cells undergo rapid cell death. Detailed analysis indicated that SNIPER(ER) caused necrotic cell death accompanied by a release of HMGB1, a marker of necrosis, from the cells. Following the ERα degradation, reactive oxygen species (ROS) was produced in the SNIPER(ER)‐treated MCF‐7 cells, and an anti‐oxidant N‐acetylcysteine inhibited the necrotic cell death. These results indicate that SNIPER(ER) induces ERα degradation, ROS production and necrotic cell death, implying a therapeutic potential of SNIPER(ER) as a lead for the treatment of ERα‐positive breast cancers.


Biology of Reproduction | 2005

Vitamin E Is Essential for Mouse Placentation but Not for Embryonic Development Itself

Kou-ichi Jishage; Takanori Tachibe; Tsuneo Ito; Norihito Shibata; Shigeo Suzuki; Toshio Mori; Toshio Hani; Hiroyuki Arai; Hiroshi Suzuki

Abstract Vitamin E (alpha-tocopherol) was discovered 80 years ago to be an indispensable nutrient for reproduction in the female. However, it has not been clarified when or where vitamin E is required during pregnancy. We examined the role of alpha-tocopherol in pregnancy using alpha-tocopherol transfer protein (Ttpa)-deficient mice fed specific alpha-tocopherol diets that led to daily, measurable change in plasma alpha-tocopherol levels from nearly normal to almost undetectable levels. A dietary supplement of alpha-tocopherol to pregnant Ttpa−/− (homozygous null) mice was shown to be essential for maintenance of pregnancy from 6.5 to 13.5 days postcoitum but found not to be crucial before or after this time span, which corresponds to initial development and maturation of the placenta. In addition, exposure to a low alpha-tocopherol environment after initiation of placental formation might result in necrosis of placental syncytiotrophoblast cells, followed by necrosis of fetal blood vessel endothelial cells. When Ttpa−/−-fertilized eggs were transferred into Ttpa+/+ (wild-type) recipients, plasma alpha-tocopherol concentrations in the Ttpa−/− fetuses were below the detection limit but the fetuses grew normally. These results indicate that alpha-tocopherol is indispensable for the proliferation and/or function of the placenta but not necessary for development of the embryo itself.


Journal of Lipid Research | 2006

Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver

Hiroaki Okazaki; Fumiko Tazoe; Sachiko Okazaki; Naoyuki Iso-O; Kazuhisa Tsukamoto; Motohiro Sekiya; Naoya Yahagi; Yoko Iizuka; Ken Ohashi; Tetsuya Kitamine; Ryu-ichi Tozawa; Toshihiro Inaba; Hiroaki Yagyu; Mitsuyo Okazaki; Hitoshi Shimano; Norihito Shibata; Hiroyuki Arai; Ryozo Nagai; Takashi Kadowaki; Jun-ichi Osuga; Shun Ishibashi

Squalene synthase (SS) is the first committed enzyme for cholesterol biosynthesis, located at a branch point in the mevalonate pathway. To examine the role of SS in the overall cholesterol metabolism, we transiently overexpressed mouse SS in the livers of mice using adenovirus-mediated gene transfer. Overexpression of SS increased de novo cholesterol biosynthesis with increased 3-hydroxy-3-methyglutaryl-CoA (HMG-CoA) reductase activity, in spite of the downregulation of its own mRNA expression. Furthermore, overexpression of SS increased plasma concentrations of LDL, irrespective of the presence of functional LDL receptor (LDLR). Thus, the hypercholesterolemia is primarily caused by increased hepatic production of cholesterol-rich VLDL, as demonstrated by the increases in plasma cholesterol levels after intravenous injection of Triton WR1339. mRNA expression of LDLR was decreased, suggesting that defective LDL clearance contributed to the development of hypercholesterolemia. Curiously, the liver was enlarged, with a larger number of Ki-67-positive cells. These results demonstrate that transient upregulation of SS stimulates cholesterol biosynthesis as well as lipoprotein production, providing the first in vivo evidence that SS plays a regulatory role in cholesterol metabolism through modulation of HMG-CoA reductase activity and cholesterol biosynthesis.


Journal of Biological Chemistry | 2013

25-Hydroxycholesterol Activates the Integrated Stress Response to Reprogram Transcription and Translation in Macrophages

Norihito Shibata; Aaron F. Carlin; Nathanael J. Spann; Kaoru Saijo; Christopher S. Morello; Jeffrey G. McDonald; Casey E. Romanoski; Mano Ram Maurya; Minna U. Kaikkonen; Michael T. Lam; Andrea Crotti; Donna Reichart; Jesse N. Fox; Oswald Quehenberger; Christian R. H. Raetz; M. Cameron Sullards; Robert C. Murphy; Alfred H. Merrill; H. Alex Brown; Edward A. Dennis; Eoin Fahy; Shankar Subramaniam; Douglas R. Cavener; Deborah H. Spector; David W. Russell; Christopher K. Glass

Background: Interferons and viral infections stimulate the production of 25-hydroxycholesterol. Results: 25-Hydroxycholesterol significantly alters cholesterol ester and sphingolipid levels and activates the integrated stress response. Conclusion: 25-Hydroxycholesterol activates the GCN2/eIF2α/ATF4 integrated stress response likely by causing cysteine depletion and/or by generating oxidative stress. Significance: Altering important membrane lipids and activating the integrated stress response may contribute to the antiviral activity of 25-hydroxycholesterol. 25-Hydroxycholesterol (25OHC) is an enzymatically derived oxidation product of cholesterol that modulates lipid metabolism and immunity. 25OHC is synthesized in response to interferons and exerts broad antiviral activity by as yet poorly characterized mechanisms. To gain further insights into the basis for antiviral activity, we evaluated time-dependent responses of the macrophage lipidome and transcriptome to 25OHC treatment. In addition to altering specific aspects of cholesterol and sphingolipid metabolism, we found that 25OHC activates integrated stress response (ISR) genes and reprograms protein translation. Effects of 25OHC on ISR gene expression were independent of liver X receptors and sterol-response element-binding proteins and instead primarily resulted from activation of the GCN2/eIF2α/ATF4 branch of the ISR pathway. These studies reveal that 25OHC activates the integrated stress response, which may contribute to its antiviral activity.


Journal of Biological Chemistry | 2017

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic IAP-dependent Protein Erasers (SNIPERs)

Nobumichi Ohoka; Keiichiro Okuhira; Masahiro Ito; Katsunori Nagai; Norihito Shibata; Takayuki Hattori; Osamu Ujikawa; Kenichiro Shimokawa; Osamu Sano; Ryokichi Koyama; Hisashi Fujita; Mika Teratani; Hirokazu Matsumoto; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito

Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies on selective degradation of pathogenic proteins via small chimeric molecules linking an E3 ubiquitin ligase to the targeted protein for proteasomal degradation. To this end, we recently developed a protein knockdown system based on hybrid small molecule SNIPERs (Specific and Nongenetic IAP-dependent Protein Erasers) that recruit inhibitor of the apoptosis protein (IAP) ubiquitin ligases to specifically degrade targeted proteins. Here, we extend our previous study to show a proof of concept of the SNIPER technology in vivo. By incorporating a high affinity IAP ligand, we developed a novel SNIPER against estrogen receptor α (ERα), SNIPER(ER)-87, that has a potent protein knockdown activity. The SNIPER(ER) reduced ERα levels in tumor xenografts and suppressed the growth of ERα-positive breast tumors in mice. Mechanistically, it preferentially recruits X-linked IAP (XIAP) rather than cellular IAP1, to degrade ERα via the ubiquitin-proteasome pathway. With this IAP ligand, potent SNIPERs against other pathogenic proteins, BCR-ABL, bromodomain-containing protein 4 (BRD4), and phosphodiesterase-4 (PDE4) could also be developed. These results indicate that forced ubiquitylation by SNIPERs is a useful method to achieve efficient protein knockdown with potential therapeutic activities and could also be applied to study the role of ubiquitylation in many cellular processes.


Bioorganic & Medicinal Chemistry Letters | 2016

Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand

Yosuke Demizu; Norihito Shibata; Takayuki Hattori; Nobumichi Ohoka; Hiromi Motoi; Takashi Misawa; Takuji Shoda; Mikihiko Naito; Masaaki Kurihara

The manipulation of protein stability with small molecules has great potential as a technique for aiding the development of clinical therapies, including treatments for cancer. In this study, BCR-ABL protein degradation inducers called SNIPER(ABL) (Specific and Non-genetic inhibitors of apoptosis protein [IAP]-dependent Protein Erasers) were developed. The designed molecules contained two biologically active scaffolds: one was an imatinib derivative that binds to BCL-ABL and the other was a methyl bestatin that binds to cellular IAP 1 (cIAP1). The hybrid molecules, SNIPER(ABL), were expected to recruit BCR-ABL to cIAP1 for removal by proteasomes. In fact, SNIPER(ABL) induced the degradation of BCR-ABL protein and a subsequent reduction in cell growth. Thus, the degradation of BCR-ABL by SNIPER(ABL) is one potential strategy for treating BCR-ABL driven chronic myelogenous leukemia.

Collaboration


Dive into the Norihito Shibata's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nobuo Cho

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hiroshi Nara

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Katsunori Nagai

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Osamu Ujikawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kenichiro Shimokawa

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge